PDS Biotech to present updated Versamune HPV Phase 2 data at ASTRO 2024

PDS Biotechnology Corp

Updated IMMUNOCERV Phase 2 data for Versamune® HPV (PDS0101) with chemoradiation in locally advanced cervical cancer accepted for oral presentation at ASTRO 2024.
Presentation scheduled for Oct 1, 2024, 2:50-3:00 p.m. ET; lead author Dr. Adam Grippin from MD Anderson.
No specific efficacy results disclosed in this press release; investors await presentation for updated data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.